478 related articles for article (PubMed ID: 30511683)
1. Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Liu J; Zhao XS; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Huang XJ; Chang YJ
Chin Med J (Engl); 2018 Dec; 131(23):2808-2816. PubMed ID: 30511683
[TBL] [Abstract][Full Text] [Related]
2. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
[No Abstract] [Full Text] [Related]
3. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.
Chang YJ; Wang Y; Liu YR; Xu LP; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
J Hematol Oncol; 2017 Jul; 10(1):134. PubMed ID: 28676064
[TBL] [Abstract][Full Text] [Related]
4. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation.
Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y
Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.
Zhang Y; Wang P; Cassady K; Zou Z; Li Y; Deng X; Yang W; Peng X; Zhang X; Feng Y
Transpl Immunol; 2022 Jun; 72():101596. PubMed ID: 35390479
[TBL] [Abstract][Full Text] [Related]
6. [Effect of minimal residual disease monitoring by multiparameter flow cytometry pre-conditioning on prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Wang H; Zhao YL; Cao XY; Liu DY; Zhang JP; Xiong M; Zhou JR; Sun RJ; Wei ZJ; Ji SQ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):118-123. PubMed ID: 28279035
[No Abstract] [Full Text] [Related]
7. Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFβ/MYH11 gene expression.
Xiaosu Z; Leqing C; Yazhen Q; Yu W; Xiaohui Z; Lanping X; Xiaojun H; Yingjun C
Ann Hematol; 2019 Jan; 98(1):73-81. PubMed ID: 30159599
[TBL] [Abstract][Full Text] [Related]
8. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
9. Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.
Guo H; Chang YJ; Hong Y; Xu LP; Wang Y; Zhang XH; Wang M; Chen H; Chen YH; Wang FR; Wei-Han ; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Huang XJ
Cell Mol Immunol; 2021 May; 18(5):1172-1185. PubMed ID: 33408344
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.
Deng DX; Wen JJ; Cheng YF; Zhang XH; Xu LP; Wang Y; Yan CH; Chen YH; Chen H; Han W; Wang FR; Wang JZ; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
BMC Cancer; 2021 Mar; 21(1):292. PubMed ID: 33740924
[TBL] [Abstract][Full Text] [Related]
11. Impact of measurable residual disease in combination with CD19 on postremission therapy choices for adult t(8;21) acute myeloid leukemia in first complete remission.
Jia X; Liao N; Yu S; Li H; Liu H; Zhang H; Xu J; Yao Y; He H; Yu G; Liu Q; Zhang Y; Shi P
Cancer Med; 2024 Feb; 13(4):e7074. PubMed ID: 38457215
[TBL] [Abstract][Full Text] [Related]
12. Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.
Yu S; Fan Z; Ma L; Wang Y; Huang F; Zhang Q; Huang J; Wang S; Xu N; Xuan L; Xiong M; Han L; Sun Z; Zhang H; Liu H; Yu G; Shi P; Xu J; Wu M; Guo Z; Xiong Y; Duan C; Sun J; Liu Q; Zhang Y
JAMA Netw Open; 2021 Jul; 4(7):e2115991. PubMed ID: 34232303
[TBL] [Abstract][Full Text] [Related]
13. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
14. Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL.
Li SQ; Fan QZ; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Liu YR; Mo XD; Wang XY; Liu KY; Huang XJ; Chang YJ
Front Oncol; 2020; 10():320. PubMed ID: 32257948
[No Abstract] [Full Text] [Related]
15. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
16. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
Shen X; Pan J; Qi C; Feng Y; Wu H; Qian S; Lu H; Chen L; Li J; Miao K; Qiu H; Zhu H
Hematology; 2021 Dec; 26(1):295-300. PubMed ID: 33648437
[TBL] [Abstract][Full Text] [Related]
17. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
18. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
Cho BS; Yahng SA; Min GJ; Park S; Park SS; Shin SH; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
Transplant Cell Ther; 2021 Sep; 27(9):774.e1-774.e12. PubMed ID: 34082159
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.
Bai L; Zhang YZ; Yan CH; Wang Y; Xu LP; Zhang XH; Zhang LP; Huang XJ; Cheng YF
BMC Cancer; 2022 Aug; 22(1):896. PubMed ID: 35974319
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML.
Anthias C; Dignan FL; Morilla R; Morilla A; Ethell ME; Potter MN; Shaw BE
Bone Marrow Transplant; 2014 May; 49(5):679-83. PubMed ID: 24510069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
